Haisen Bio Completes MAT Transfers for 11 Products Across Asia-Pacific, Accelerating Global Commercial Ecosystem Buildout
On June 16, 2025, Haisen Biopharma Co., Ltd. (hereinafter referred to as “Haisen Biopharma”) announced that its overseas affiliate, Haisen Biopharmaceuticals (Asia) Co., Ltd., had successively completed the Market Authorization Transfers (MAT) for 11 products in multiple countries and regions across the Asia-Pacific, including Malaysia, Singapore, the Philippines, and Hong Kong, China, during the first half of this year. This move accelerates the establishment of a global commercial ecosystem radiating across the Asia-Pacific region, bringing high-quality products and solutions to more patients.
Products that have currently received Marketing Authorization (MA) approval in multiple Asia-Pacific regions primarily cover chronic disease areas such as cardiovascular diseases and diabetes, e.g., Actos.®, Actosmet®, Blopress®, Blopress Plus®, Nesina®, Nesinamet®, Ubretid®, Unisia®, Albothyl®, Edarbi®, Oseni®etc. Haisheng Biotech will leverage its established expertise in regulatory submissions, manufacturing transfer, and marketing across the Asia-Pacific region to provide efficient and professional services that accelerate local operations and commercialization for global biopharmaceutical partners, thereby facilitating the early realization of its Asia-Pacific development strategy.
As an innovative biopharmaceutical enterprise, Haisen Bio anchors its strategy in high-demand segments of the global biopharmaceutical market, focusing on chronic diseases and acute/critical care conditions to continuously enhance commercial conversion efficiency. In terms of commercialization strategy, Haisen Bio not only engages in multi-dimensional strategic collaborations within mainland China but also successfully acquired the commercial rights for multiple branded pharmaceutical products across eight countries and regions in the Asia-Pacific in June 2024. By leveraging these acquisitions to establish robust Asia-Pacific distribution channels, the company has achieved a diversified commercial layout and currently boasts a mature and experienced professional overseas team. These effective international expansion experiences are expected to consolidate the company’s potential, provide replicable business models for more pipeline assets, and drive sustainable development.
Rooted in China, with a global vision. Haisen Biologics is actively accelerating the launch of relevant products in other Asia-Pacific rights regions, further deepening its pan-Asia-Pacific commercial footprint by continuously enhancing its influence and enriching the lifecycle of its product pipeline, thereby serving more patients and striving to become a leading healthcare company with outstanding international commercialization capabilities at an early date.
Haisen Biopharma Co., Ltd. (hereinafter referred to as “Haisen Biopharma”) is an innovative biopharmaceutical company established in 2020, with its business focused on chronic diseases and acute/critical care conditions. The company is committed to becoming a leading commercial platform and innovation driver in the biopharmaceutical industry. Adhering to a patient-centric value proposition, Haisen Biopharma leverages sustainable commercial capabilities to accelerate the value realization of high-quality products, deliver innovative therapeutic solutions, safeguard patient health, and jointly create societal health value.